ScoreWhy is Senores Pharmaceuticals Ltd ?
1
Company has a Debt to Equity ratio (avg) of 0.10 times
2
Healthy long term growth as Net Sales has grown by an annual rate of 71.70% and Operating profit at 108.34%
3
The company has declared Positive results for the last 5 consecutive quarters
- NET SALES(9M) Higher at Rs 526.35 cr
- PAT(9M) Higher at Rs 93.99 Cr
- PBDIT(Q) Highest at Rs 53.76 cr.
4
With ROCE of 13.5, it has a Very Expensive valuation with a 5.8 Enterprise value to Capital Employed
- Over the past year, while the stock has generated a return of 95.54%, its profits have risen by 97% ; the PEG ratio of the company is 0.5
5
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 3.14% over the previous quarter and collectively hold 16.39% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
6
Market Beating Performance
- The stock has generated a return of 95.54% in the last 1 year, much higher than market (BSE500) returns of 2.91%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Senores Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Senores Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Senores Pharma.
95.54%
2.35
40.58%
Sensex
-3.2%
-0.24
13.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
71.70%
EBIT Growth (5y)
108.34%
EBIT to Interest (avg)
4.97
Debt to EBITDA (avg)
3.61
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.42
Tax Ratio
23.99%
Dividend Payout Ratio
0
Pledged Shares
2.81%
Institutional Holding
16.39%
ROCE (avg)
9.51%
ROE (avg)
9.90%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
50
Industry P/E
37
Price to Book Value
6.71
EV to EBIT
38.83
EV to EBITDA
32.04
EV to Capital Employed
5.77
EV to Sales
9.37
PEG Ratio
0.51
Dividend Yield
NA
ROCE (Latest)
13.47%
ROE (Latest)
12.36%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
NET SALES(9M)
Higher at Rs 526.35 cr
PAT(9M)
Higher at Rs 93.99 Cr
PBDIT(Q)
Highest at Rs 53.76 cr.
-5What is not working for the Company
INTEREST(9M)
At Rs 20.96 cr has Grown at 26.80%
Loading Valuation Snapshot...
Here's what is working for Senores Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 62.33 cr has Grown at 65.95%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 180.21 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 53.76 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Here's what is not working for Senores Pharma.
Interest - Latest six months
At Rs 15.63 cr has Grown at 35.68%
over previous Half yearly periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
